Progyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027

Progyny remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility.

PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating.

Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.

Upcoming catalysts include the rollout of Progyny Select for smaller employers and potential multiple expansion as new revenue streams materialize in 2027.

Based in New York City and founded in 2008, Progyny, Inc. (PGNY) remains the leading go-to provider of fertility benefits to company employees in the US.

PGNY stock is currently experiencing a 14% drawdown from recent